Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31,887,528
-
Total 13F shares
-
965,701
-
Share change
-
+965,701
-
Total reported value
-
$1,806,003
-
Price per share
-
$1.87
-
Number of holders
-
28
-
Value change
-
+$1,806,005
-
Number of buys
-
28
Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) as of Q2 2023
As of 30 Jun 2023,
Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
965,701 shares.
The largest 10 holders included
VANGUARD GROUP INC, GSA CAPITAL PARTNERS LLP, BlackRock Inc., MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, Y-Intercept (Hong Kong) Ltd, Cubist Systematic Strategies, LLC, RHUMBLINE ADVISERS, and STATE STREET CORP.
This page lists
29
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.